<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="390">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on March 04, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05084495</url>
  </required_header>
  <id_info>
    <org_study_id>Tambocor_prosp_01</org_study_id>
    <nct_id>NCT05084495</nct_id>
  </id_info>
  <brief_title>The Use of Flecainide for Treatment of Atrial Fibrillation</brief_title>
  <official_title>Can Global Peak Longitudinal Strain Measurements in Combination With Non-invasive ECG Parameters Predict the Success or Failure of Flecainide Treatment for Atrial Fibrillation Patients?</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lund University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Lund University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This prospective observational study will include patients with atrial fibrillation that has&#xD;
      indication for treatement with flecainide. Included patients are followed during a 12 month&#xD;
      period. During the follow-up period they will have four clinical visits, during which&#xD;
      clinical data, advanced echocardiographic data (strain and speckle tracking) and ECGs&#xD;
      (Glasgow criteria) will be collected. These data will be analysed in relation to outcome&#xD;
      parameters as: maintaining a normal sinus rhythm (arrythmia free health status), number of&#xD;
      AF-free months, chances of successful electrical cardioversion, frequency of side effects,&#xD;
      risk of pro-arrhythmias and mortality. The importance of these two analyses is to improve the&#xD;
      use of flecainide. Hence, today patients with low benefit compared to risk of adverse events&#xD;
      are inappropriately treated with flecainide with the &quot;trial and error&quot; approach currently&#xD;
      used. On the other hand flecainide is currently underutilized, and patients denied the&#xD;
      treatment that could improve their quality of life, prognosis and reduce their risk of&#xD;
      cardiovascular adverse events. By investigating novel and promising parameters there is the&#xD;
      potential of a better prediction of initiating safe and accurate anti-arrhythmic therapy for&#xD;
      patients with atrial fibrillation.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study synopsis for the Tambocor Prospective study&#xD;
&#xD;
      Inclusion: Patients with atrial fibrillation that admitted to the ward for prior to start of&#xD;
      flecainide initiation.&#xD;
&#xD;
      Ethics: Informed Concent prior to inclusion.&#xD;
&#xD;
      Follow up after baseline: 4 visits during 12 month.&#xD;
&#xD;
      End points : Side effects that lead to discontinuation of flecainide. Persistent AF that lead&#xD;
      to discontinuation of flecainide.&#xD;
&#xD;
      Evaluated parameters: 12 lead ECG, ECHO: LA, LV, HV strain , Dynamic Heart model: LV and RV.&#xD;
&#xD;
      The follow up visits:&#xD;
&#xD;
      Baseline: Normal ECHO after the first dose of flecainide, ECG and Questionnaire&#xD;
&#xD;
      4 Weeks: Normal ECHO + Protocol ECHO (LA, LV, HV strain , Dynamic Heart model: LV and RV) and&#xD;
      Questionnaire.&#xD;
&#xD;
      6 month: Normal ECHO + Protocol ECHO (LA, LV, HV strain , Dynamic Heart model: LV and RV) and&#xD;
      Questionnaire.&#xD;
&#xD;
      12 month: Normal ECHO + Protocol ECHO (LA, LV, HV strain , Dynamic Heart model: LV and RV)&#xD;
      and Questionnaire.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">February 2022</start_date>
  <completion_date type="Anticipated">October 2025</completion_date>
  <primary_completion_date type="Anticipated">October 2025</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Arrythmia free health status</measure>
    <time_frame>During the 12 month follow up</time_frame>
    <description>Can we predict who will maintain a normal sinus rhythm prior to initiation of flecainide? treatment start</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of AF-free months</measure>
    <time_frame>During the 12 month follow up</time_frame>
    <description>Can we improve the number of AF-free months by a better prediction model</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of side effects</measure>
    <time_frame>During the 12 month follow up</time_frame>
    <description>Can we improve the diagnostic accuracy to reduce the frequency of side effects</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Risk of pro-arrhythmias</measure>
    <time_frame>During the 12 month follow up</time_frame>
    <description>Can we improve the diagnostic accuracy to reduce risk of pro-arrhythmias</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>During the 12 month follow up</time_frame>
    <description>Can we improve the diagnostic accuracy to reduce risk mortality</description>
  </secondary_outcome>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Atrial Fibrillation</condition>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Global peak atrial longitudinal strain and ECG</intervention_name>
    <description>During the follow-up period the patient will have four clinical visits, during which clinical data, advanced echocardiographic data (strain and speckle tracking) and ECGs (Glasgow criteria) will be collected</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Normally, the heart contracts and relaxes regularly. When atrial fibrillation (AF) occurs,&#xD;
        the it start to beat irregularly and untreated AF doubles the risk of heart-related deaths.&#xD;
        Flecainide is a class IC anti-arrhythmic drug approved in Europe since 1982, first for&#xD;
        suppression and prevention of ventricular arrhythmia, after its use was extended to also&#xD;
        treat supra-ventricular arrhythmia's. It can be used as the rhythm control strategy in AF&#xD;
        management of patients without structural heart disease. This population will be studied to&#xD;
        try to improve the use of the drug and improve the chance to maintaining a normal sinus&#xD;
        rhythm (arrhythmia free health status), number of AF-free months, chances of successful&#xD;
        electrical cardioversion, reduce frequency of side effects, risk of pro-arrhythmia's and&#xD;
        mortality.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  All patients with written informed consent who are eligible for flecainide treatment&#xD;
             for atrial fibrillation.&#xD;
&#xD;
          -  The patients must be followed at the Sk책nes hospitals northwest and Sk책nes university&#xD;
             hospitals.&#xD;
&#xD;
          -  Age &gt;18 years&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Flecainide treatment with other indication than atrial fibrillation (including atrial&#xD;
             flutter).&#xD;
&#xD;
          -  No secure date for treatment start.&#xD;
&#xD;
          -  Age &lt;18 years&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Bjarne Madsen H채rdig, RN, PhD</last_name>
    <phone>+46 42 4061613</phone>
    <email>bjarne.madsen_hardig@med.lu.se</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Alexander Siotis, MD</last_name>
    <phone>+46 42 4061223</phone>
    <email>alexander.siotis@med.lu.se</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Clinical Sciences, Helsingborg Medical Faculty Lund University</name>
      <address>
        <city>Helsingborg</city>
        <state>Skane</state>
        <zip>25187</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <contact>
      <last_name>Bjarne Madsen H채rdig, RN, PhD</last_name>
      <phone>+46 42 4061613</phone>
      <email>bjarne.madsen_hardig@med.lu.se</email>
    </contact>
    <contact_backup>
      <last_name>Alexander Siotis, MD</last_name>
      <phone>+46 42 4061223</phone>
      <email>alexander.siotis@med.lu.se</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <reference>
    <citation>Andrikopoulos GK, Pastromas S, Tzeis S. Flecainide: Current status and perspectives in arrhythmia management. World J Cardiol. 2015 Feb 26;7(2):76-85. doi: 10.4330/wjc.v7.i2.76. Review.</citation>
    <PMID>25717355</PMID>
  </reference>
  <reference>
    <citation>Aliot E, Capucci A, Crijns HJ, Goette A, Tamargo J. Twenty-five years in the making: flecainide is safe and effective for the management of atrial fibrillation. Europace. 2011 Feb;13(2):161-73. doi: 10.1093/europace/euq382. Epub 2010 Dec 7. Review.</citation>
    <PMID>21138930</PMID>
  </reference>
  <reference>
    <citation>Cardiac Arrhythmia Suppression Trial (CAST) Investigators. Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. N Engl J Med. 1989 Aug 10;321(6):406-12.</citation>
    <PMID>2473403</PMID>
  </reference>
  <reference>
    <citation>Macfarlane PW, Devine B, Latif S, McLaughlin S, Shoat DB, Watts MP. Methodology of ECG interpretation in the Glasgow program. Methods Inf Med. 1990 Sep;29(4):354-61.</citation>
    <PMID>2233383</PMID>
  </reference>
  <reference>
    <citation>Skov MW, Ghouse J, K체hl JT, Platonov PG, Graff C, Fuchs A, Rasmussen PV, Pietersen A, Nordestgaard BG, Torp-Pedersen C, Hansen SM, Olesen MS, Hauns첩 S, K첩ber L, Gerds TA, Kofoed KF, Svendsen JH, Holst AG, Nielsen JB. Risk Prediction of Atrial Fibrillation Based on Electrocardiographic Interatrial Block. J Am Heart Assoc. 2018 May 30;7(11). pii: e008247. doi: 10.1161/JAHA.117.008247.</citation>
    <PMID>29848496</PMID>
  </reference>
  <reference>
    <citation>Kuppahally SS, Akoum N, Burgon NS, Badger TJ, Kholmovski EG, Vijayakumar S, Rao SN, Blauer J, Fish EN, Dibella EV, Macleod RS, McGann C, Litwin SE, Marrouche NF. Left atrial strain and strain rate in patients with paroxysmal and persistent atrial fibrillation: relationship to left atrial structural remodeling detected by delayed-enhancement MRI. Circ Cardiovasc Imaging. 2010 May;3(3):231-9. doi: 10.1161/CIRCIMAGING.109.865683. Epub 2010 Feb 4.</citation>
    <PMID>20133512</PMID>
  </reference>
  <verification_date>January 2022</verification_date>
  <study_first_submitted>October 18, 2021</study_first_submitted>
  <study_first_submitted_qc>October 18, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 19, 2021</study_first_posted>
  <last_update_submitted>January 31, 2022</last_update_submitted>
  <last_update_submitted_qc>January 31, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">February 15, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

